» Articles » PMID: 22776291

The Cargo of CRPPR-conjugated Liposomes Crosses the Intact Murine Cardiac Endothelium

Overview
Specialty Pharmacology
Date 2012 Jul 11
PMID 22776291
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Ligand-conjugated liposomes and other nano-sized constructs are attractive drug carriers due to their extended plasma circulation; however, limited data are available as to whether their cargo can traverse the endothelium of solid organs. To determine whether the cargo of endothelially targeted liposomes is internalized by endothelial cells and transported into tissue, and to evaluate whether such liposomes can accumulate in models of cardiovascular disease, we tracked the fate of the cargo (a hydrophilic fluorescent dye) and shell (conjugated with a radioisotope) of a heart-homing liposome (CRPPR-conjugated). The ex vivo heart was imaged with confocal microscopy and the in vivo heart with positron emission tomography in sham-treated mice and models of ischemia/reperfusion (I/R) and myocardial infarction (MI). Within 30 min of injection of 20mg/kg CRPPR liposomes, fluorescence increased by 47 fold in the tissue surrounding the vascular lumen, as compared with non-targeted liposomes. Both the accumulation on the endothelium and the interstitial fluorescence saturated at an injected dose of 20mg/kg. In both I/R and MI models, CRPPR liposomes accumulated in diseased sites, although less than in surrounding healthy tissue. The accumulation in the diseased sites increased with time post-injury: the ratio of accumulated radioactivity in the diseased and healthy cardiac tissue increased from 0.20±0.04, to 0.58±0.12 and 0.61±0.19 for 1, 7, and 99 days post-MI, indicating the potential for adequate delivery and therapeutic efficacy if the targeted particles are injected at 7 or more days post-MI. In summary, CRPPR- liposomes accumulated in normal and diseased hearts, and the cargo accumulated in the tissue within minutes and remained detectable after 24 h.

Citing Articles

Design and synthesis of cyclic lipidated peptides derived from the C-terminus of Cx43 for hemichannel inhibition and cardiac endothelium targeting.

Iaculli D, Montgomery J, Lamouroux A, Caufriez A, Gozalbes R, Vinken M RSC Med Chem. 2025; .

PMID: 39829973 PMC: 11740094. DOI: 10.1039/d4md00850b.


Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review.

Rodriguez-Castejon J, Beraza-Millor M, Solinis M, Rodriguez-Gascon A, Del Pozo-Rodriguez A Drug Deliv Transl Res. 2024; 14(10):2615-2628.

PMID: 38587758 PMC: 11383842. DOI: 10.1007/s13346-024-01583-0.


Evaluation and manipulation of tissue and cellular distribution of cardiac progenitor cell-derived extracellular vesicles.

Roefs M, Heusermann W, Brans M, Blok C, Lei Z, Vader P Front Pharmacol. 2022; 13:1052091.

PMID: 36506565 PMC: 9729535. DOI: 10.3389/fphar.2022.1052091.


Small non-coding RNA therapeutics for cardiovascular disease.

Shah A, Giacca M Eur Heart J. 2022; 43(43):4548-4561.

PMID: 36106499 PMC: 9659475. DOI: 10.1093/eurheartj/ehac463.


Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation.

Wang J, Yu L, Zhou A, Liu J, Wang K, Luo Y Pharmaceutics. 2021; 13(9).

PMID: 34575595 PMC: 8465433. DOI: 10.3390/pharmaceutics13091520.


References
1.
Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S . Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A. 2002; 99(3):1527-31. PMC: 122224. DOI: 10.1073/pnas.241655998. View

2.
Liehn E, Postea O, Curaj A, Marx N . Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol. 2011; 58(23):2357-62. DOI: 10.1016/j.jacc.2011.08.034. View

3.
Schmidt N, Mishra A, Lai G, Wong G . Arginine-rich cell-penetrating peptides. FEBS Lett. 2009; 584(9):1806-13. DOI: 10.1016/j.febslet.2009.11.046. View

4.
Rajotte D, Ruoslahti E . Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem. 1999; 274(17):11593-8. DOI: 10.1074/jbc.274.17.11593. View

5.
Arap W, Pasqualini R, Ruoslahti E . Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279(5349):377-80. DOI: 10.1126/science.279.5349.377. View